Aurealis Pharma Announces 5.6MCHF Series A Financing

29.08.2017 16:40

Related tags

Clinical Trials

The proceeds will enable Aurealis Pharma to advance its chronic wound treatment AUP-16 into clinical trial application (CTA) filing and its cancer lead candidate AUP-5550 into non-clinical safety and efficacy studies.

Aurealis Pharma, a private biopharmaceutical company developing novel combination biologics for chronic inflammation and cancer, announced today the closing of 5.6MCHF Series A funding. The funding was provided by Swiss and foreign private investors, Finnvera plc and Tekes - the Finnish Funding Agency for Innovation. “We are very pleased to have closed this funding from an outstanding group of existing and new investors who recognize the wide potential of our technology platform and the promise of our clinical candidate AUP-16 and cancer lead AUP-5550. This financing will be used to advance AUP-16 into CTA filing in chronic wound patients by Q2 / 2018 and AUP-5550 into non-clinical proof-of-concept stage", said Dr. Juha Yrjänheikki, CEO of Aurealis Pharma.

“We find Aurealis Pharma to be a potential game-changer in the evolving chronic inflammation and cancer multitherapy landscape,” said Dr. Silvio Indcrbitzin, Investor and Board Director representing Swiss investors. “We believe this company, with its technology and diverse product portfolio is well positioned to test the combination biologics hypothesis in the clinic and prone to significant value creation.”

“It has been exciting to see the momentum build among investors, pharma and clinical key opinion leaders as we have shown more and more concrete data on our products. We remain committed to advance these products into patients suffering from these devastating diseases." continued Dr. Thomas Wirth, founder, CSO and Chairman of the Board of Aurealis Pharma.

About Aurealis Pharma
Aurealis Pharma is a Basel, Switzerland and Kuopio, Finland based privately-held biopharmaceutical company focusing on developing broadly applicable proprietary technology to re-educate the distorted host immune microenvironment in chronic inflammation and cancer to its proper state. Company's technology is based on safe food-grade lactic acid bacteria delivering multiple human therapeutic proteins in target tissue effectively, safely and economically to address the unmet medical need in chronic wounds and cancer.

(Press release)

Please login or
register to comment

Please login or sign up to comment. Commenting guidelines

Please login or
register to use the
bookmark feature

Related tags

Read more about

Principal

Partners

Contributors